 SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM products for cancer, today announced that management plans to participate in three upcoming investor conferences. 